Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| ANSM | Other Identifier | 2023-A01288-37 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Diabetes, obesity and metabolic syndrome are closely linked to sleep apnea syndrome. Indeed, diabetic and/or obese patients present an increased risk of sleep apnoea syndrome (SAS), with a prevalence estimated at between 10 and 22%, depending on the study, and most of them requiring treatment with Continuous Positive Airway Pressure (CPAP). In this sub-population of patients, only between 40% and 50% benefit from CPAP.
There is therefore an under-referral of diabetic patients to treatment, perhaps linked to the way care is organized, which clogs up the circuit and slows down or even prevents access to care. The investigators would like to test a new organization of care to facilitate and intensify this screening.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| WITHINGS Sleep Analyzer | Experimental | The sleep apnea screening device used is a medical screening device WITHINGS Sleep Analyzer (WSA) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| WITHINGS Sleep Analyzer | Device | Potentially eligible patients will be offered to participate in the study, the information leaflet will be given to them and the informed consent form will be signed if the patient agrees to participate in the study. In hospitalization in Endocrinology:
|
| Measure | Description | Time Frame |
|---|---|---|
| patients real positive for each screening technique | Percentage of patients real positive for each screening technique: BERLIN and EPWORTH score and Withings Sleep Analyzer addressed for polysomnography | Day 2 |
| Measure | Description | Time Frame |
|---|---|---|
| Number of tests | Number of positive tests / Number of analyzable test for screening for each type of test | Day 2 |
| Patient's experience with the use of Withings Sleep Analyzer | Patients' experience is evaluated using a questionnaire with the following possible answers: yes a lot, yes a little, not at all. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Natacha GERMAIN, MD-PhD | CHU de Saint-Etienne | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHU de Saint-Etienne | Saint-Etienne | 42055 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
|
| Day 2 |
| Nurse's satisfaction with the use of Withings Sleep Analyzer | Nurse's satisfaction is evaluated using a questionnaire with the following possible answers: yes a lot, yes a little, not at all. | 3 months |
| ID | Term |
|---|---|
| D012891 | Sleep Apnea Syndromes |
| D024821 | Metabolic Syndrome |
| D003920 | Diabetes Mellitus |
| D009765 | Obesity |
| ID | Term |
|---|---|
| D001049 | Apnea |
| D012120 | Respiration Disorders |
| D012140 | Respiratory Tract Diseases |
| D020919 | Sleep Disorders, Intrinsic |
| D020920 | Dyssomnias |
| D012893 | Sleep Wake Disorders |
| D009422 | Nervous System Diseases |
| D007333 | Insulin Resistance |
| D006946 | Hyperinsulinism |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
| D050177 | Overweight |
| D044343 | Overnutrition |
| D009748 | Nutrition Disorders |
| D001835 | Body Weight |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided